宫颈癌免疫治疗的研究进展

牛 云, 金艳 霞*
青海大学附属医院

摘要


宫颈癌当前在中国女性恶性肿瘤中发病率位居第五，而在妇科恶性肿瘤中发病率与死亡率均位列第一，其
治疗仍存在诸多限制，特别是复发或转移性宫颈癌。不同于传统的手术，放疗和化疗路径。免疫治疗试图从“病
毒-免疫-肿瘤”这层关系切入，打破传统的体外治疗。随着诊疗技术的不断进步，人们对肿瘤发病机制有了更深
一步的了解，免疫治疗成为恶性肿瘤的治疗新方法，也成为宫颈癌治疗的研究热点。本文将简要综述宫颈癌及复发
或转移性宫颈癌的免疫治疗新方法。

关键词


宫颈癌；免疫治疗；免疫检查点抑制剂；过继性细胞治疗；治疗性疫苗；联合治疗

全文:

PDF


参考


[1]向阳，宗丽菊.免疫检查点抑制剂在妇科恶性肿

瘤中的应用现状及展望[J].中国实用妇科与产科杂志，

2019，35（1）：17-22.

[2]刘萍，白惠君.子宫颈癌的免疫治疗[J].中国实用

妇科与产科杂志，2024，40（1）：41-44.

[3]张远丽，张玉敏，张师前.2019年泰山科技论坛

专家观点——妇科肿瘤的当下与未来[J].中国实用妇科与

产科杂志，2019，35（12）：1401-1405.

[4]宗丽菊，向阳.晚期及复发宫颈癌免疫治疗的研

究进展与未来[J].中国实用妇科与产科杂志，2018，34

（11）：1211-1216

[5]Bordignon V, Di Domenico EG, Trento E, et al.

How human papillomavirus replication and immune evasion

strategies take advantage of the host DNA damage repair

machinery[J]. Viruses, 2017, 9(12): 390.

[6]Kalbasi A, Ribas A. Tumour-intrinsic resistance to

immune checkpoint blockade [J]. Nature Reviews Immunology,

2020, 20 (1): 25-39.

39

医学理论研究 | 第3卷/第5期

Medical Theory Research

[7]Liu C, Chikina M, Deshpande R, et al.Treg cells

promote the SREBP1 dependent metabolic fitness of tumor_xfffe_promoting macrophages via repression of CD8 + T cell-derived

interferon-γ [J]. Immunity, 2019, 51(2): 381-397. e6.

[8]Patel R, Kim K, Shutinoski B, et al. Culling of APCs

by inflammatory cell death pathways restricts TIM3 and PD-1

expression and promotes the survival of primed CD8 T cells [J].

Cell Death ＆ Differentiation, 2017, 24(11): 1900-1911.

[9]Elia G, Ferrari SM, Galdiero MR, Ragusa F, Paparo

SR, Ruffilli I, Varricchi G, Fallahi P, Antonelli A. New insight

in endocrine-related adverse events associated to immune

checkpoint blockade. Best Pract Res Clin Endocrinol Metab.

2020 Jan; 34(1): 101370. doi: 10.1016/j.beem.2019.101370

[10]Korman AJ, Peggs KS, Allison JP.Checkpoint

blockade in cancer immunotherapy[J].Adv Immunol, 2006,

90:297-339

[11]Wei SC, Levine JH, Cogdill AP, et al.Distinct

cellular mechanisms underlie anti-CTLA-4 and anti-PD-1

checkpoint blockade[J].Cell, 2017, 170(6): 1120-1133

[12]Chung HC, Ros W, Delord JP, et al.Efficacy and

safety of pembrolizumab in previously treated advanced

cervical cancer: results from the phase II KEYNOTE-

158study[J].J Clin On col, 2019, 37(17): 1470-1478.

[13]Colombo N, Dubot C, Lorusso D, et al.

Pembrolizumab for per-sistent, recurrent, or metastatic

cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867.

DOI: 10.1056/NEJMoa2112435.

[14]Tewari KS, Colombo N, Monk BJ, et al.

Pembrolizumab+chemotherapy in patients withpersistent,

recurrent, or metastatic cervi-cal cancer: Subgroup analysis

of keynote-826[J]. J Clin Oncol, 2022, 40(16_supp l): 5506.

DOI: 10.1200/JCO.2022.40.16_suppl.5506.

[15]周晖，刘昀昀，罗铭，等.《2022 NCCN子宫颈

癌临床实践指南（第1版）》解读[J].中国实用妇科与产

科杂志，2021，37（12）：1220-1226.

[16]Lheureux S, Butler MO, Clarke B, et al. Association

of ipi-limumab with safety and antitumor activity in women

withmetastatic or recurrent human papillomavirus-related

cervicalcarcinoma[J]. JAMA Oncol, 2018, 4(7): e173776.

DOI: [10].01/jamaoncol.2017.3776.

[17]Mayadev JS, Enserro D, Lin YG, et al. Sequential

ipilimumabafter chemoradiotherapy in curative-intent treat_xfffe_ment of patientswith node-positive cervical cancer[J]. JAMA

Oncol, 2020, 6(1): 92-99. DOI: 10.1001/jamaoncol.2019.3857.

[18]Wu XH, J JF, L HM, et al. Efficacy and safety of

cadonilimab, an anti-PD-1/CTLA4 bispecific antibody, in

pre-viously treatedrecurrent or metastatic (R/M) cervical

cancer: A multicenter, open-label, single-arm, phase Ⅱ

trial(075)[J]. Gynecol Oncol, 2022, 166(Suppl 1): S47-S48.

DOI: 10.1016/S0090-8258(22)01293-8.

[19]中国临床肿瘤学会指南工作委员会.《CSCO免

疫检查点抑制剂临床应用指南2025》.

[20]VAN POELGEEST M I, VISCONTI V V, AGHAI

Z, et al. Potential use of lymph node-derived HPV-specificT

cells for adoptive cell therapy of cervical cancer[J].Cancer

Immunol Immunother, 2016, 65(12): 1451-1463.

[21]STEVANOVIĆ S, DRAPER L M, LANGHAN M

M, et al. Complete regression of metastatic cervical cancerafter

treatment with human papillomavirus-targetedtumor-infiltrating

T cells [J]. J Clin Oncol, 2015, 33(14): 1543-1550.

[22]王雨蒙，刘宝瑞，刘芹.肿瘤新抗原特异性过继

性细胞免疫治疗的研究进展[J].中华肿瘤杂志，2025，47

（4）：298-307. DOI：10.3760/cma.j.cn112152-20240924-

00412.

[23]Bhuyan PK, Dallas M, Kraynyak K, et al. Durability

of re-sponse to VGX-3100 treatment of HPV16/18 positive

cervical HSIL[J].Hum Vaccin Immunother, 2021, 17(5):

1288-1293. DOI:10. 1080/21645515. 2020. 1823778.

[24]Trimble CL, Morrow MP, Kraynyak KA, et al. Safety,

efficacy, and immunogenicity of VGX-3100, a therapeutic

synthetic DNA vaccine targeting human papillomavirus 16

and 18 E6 and E7 proteins for cervical intraepithelial neoplasia

2/3:A ran-domised, double-blind, placebo-controlled phase

2b trial[J]. Lancet, 2015, 386(10008): 2078-2088. DOI:10.

1016/S0140 6736(15)00239-1.

[25]Brun JL, Dalstein V, Leveque J, et al. Regression

of high grade cervical intraepithelial neoplasia with TG4001

targeted immunotherapy[J]. Am J Obstet Gynecol, 2011,

204(2): 169. DOI:10. 1016/j. ajog. 2010. 09. 020.

[26]Borcoman E, Lalanne A, Delord JP, et al. Phase

Ⅰb/Ⅱ trial of tipapkinogene sovacivec, a therapeutic human

papillomavi-rus16-vaccine, in combination with avelumab

40

in patients with advanced human papillomavirus16-positive

cancers[J]. Eur J Cancer, 2023, 191: 112981. DOI: 10. 1016/j.

ejca. 2023. 112981.

[27]Wang J, Wang Q, Ma L, et al. Development of an

mRNA based therapeutic vaccine mHTV-03E2 for highrisk HPV related malignancies[J]. Mol Ther, 2024, 32(7):

2340-2356. DOI:10. 1016/j. ymthe. 2024. 04. 036.

[28]Zhao L, Zhang M, Cong H. Advances in the study of

HLA restricted epitope vaccines[J]. Hum Vaccin Immunother,

2013, 9(12): 2566-2577. DOI:10. 4161/hv. 26088.

[29]Perenkov AD, Sergeeva AD, Vedunova MV, et

al. In Vitro Tran-scribed RNA-Based Platform Vaccines:

Past, Present, and Fu-ture[J]. Vaccines, 2023, 11(10): 1600.

DOI:10. 3390/vac-cines11101600.

[30]Branda F, Pavia G, Ciccozzi A, et al. Human

Papillomavirus (HPV) Vaccination: Progress, Challenges, and

Future Direc-tions in Global Immunization Strategies[J].

Vaccines, 2024, 12 (11): 1293. DOI:10. 3390/vaccines12111293.

[31]Zhu L, Cui X, Yan Z, et al. Design and evaluation

of a multi epitope DNA vaccine against HPV16[J]. Hum

Vaccin Immu-nother, 2024, 20(1): 2352908. DOI: 10.

1080/21645515. 2024. 2352908.

[32]Ehsasatvatan M, Baghban Kohnehrouz B. Designing

and immu-nomolecular analysis of a new broad-spectrum

multiepitope vaccine against divergent human papillomavirus

types[J]. PLoS One, 2024, 19(12): e0311351. DOI:10. 1371/

journal. pone. 0311351.

[33]PENG S, FERRALL L, GAILLARD S, et

al.Development of DNA vaccine targeting E6 and E7proteins

of human papillomavirus 16 (HPV16) andHPV18 for

immunotherapy in combination withrecombinant vaccinia

boost and PD-1 antibody[J]. mBio, 2021, 12(1): e03224-20.

[34]FERRALL L, LIN K Y, RODEN R B S, et al.

Cervicalcancer immunotherapy: Facts and hopes[J]. Clin

CancerRes, 2021, 27(18): 4953-4973.

[35]O’MALLEY D M, NEFFA M, MONK B J, et

al. DualPD-1 and CTLA-4 checkpoint blockade using

balstilimaband zalifrelimab combination as second-line

treatmentfor advanced cervical cancer: An open-label phase

Ⅱstudy[J]. J Clin Oncol, 2022, 40(7): 762-771.

[36]Monk BJ, Toita T, Wu X, et al. Durvalumab versus

placebo with chemoradiotherapy for locally advanced cervical

cancer (CALLA): a randomised, double-blind, phase 3 trial[J].

Lancet Oncol, 2023, 24(12): 1334-1348. DOI: 10.1016/

S1470-2045(23)00479-5.

[37]Lorusso D, Xiang Y, Hasegawa K, et al.

Pembrolizumab or placebo with chemoradiotherapy followed

by pembrolizumab or placebo for newly diagnosed, highrisk, locally advanced cervical cancer (ENGOT-cx11/GOG-

3047/KEYNOTE-A18): a randomised, double-blind, phase

3 clinical trial[J]. Lancet, 2024, 403(1034): 1341-1350. DOI:

10.1016/S0140-6736(24)00317-9.


Refbacks

  • 当前没有refback。